Euroapi SAS
PAR:EAPI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Euroapi SAS
Cash & Cash Equivalents
Euroapi SAS
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Euroapi SAS
PAR:EAPI
|
Cash & Cash Equivalents
€113.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
309%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Cash & Cash Equivalents
€5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Cash & Cash Equivalents
€1.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
Vetoquinol SA
PAR:VETO
|
Cash & Cash Equivalents
€171m
|
CAGR 3-Years
85%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Virbac SA
PAR:VIRP
|
Cash & Cash Equivalents
€122.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
9%
|
|
|
Medincell SA
PAR:MEDCL
|
Cash & Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Euroapi SAS
Glance View
EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,342 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
See Also
What is Euroapi SAS's Cash & Cash Equivalents?
Cash & Cash Equivalents
113.8m
EUR
Based on the financial report for Dec 31, 2025, Euroapi SAS's Cash & Cash Equivalents amounts to 113.8m EUR.
What is Euroapi SAS's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
309%
Over the last year, the Cash & Cash Equivalents growth was 56%. The average annual Cash & Cash Equivalents growth rates for Euroapi SAS have been 15% over the past three years , 309% over the past five years .
